The efficacy of abemaciclib, a CDK4/6 inhibitor, has been proven, and abemaciclib was well tolerated in breast cancer and endometroid endometrial cancer when combined with aromatase inhibitors in a phase II trial. The gene discussed is CYP19A1; the disease is breast carcinoma.